Becky Noel is the Global Lead of the Benefit-Risk Assessment group at Eli Lilly and Company, where she and her team are responsible for providing benefit-risk assessment support across the Lilly portfolio. Since 2005, Becky has been extensively involved in developing and promoting systematic methods for benefit-risk assessment, both internally at Lilly and externally via the PhRMA Benefit-Risk Action Team (BRAT), the PhRMA Benefit-Risk Global Convergence issues team, the Center for Innovation in Regulatory Science (CIRS) Benefit-Risk Task Force, and the Innovative Medicines Initiative work stream devoted to benefit-risk assessment and the IMI project focused on the use of patient preferences. Along with other Lilly colleagues, Becky also recently edited and contributed to the book, Benefit-Risk Assessment in Pharmaceutical Research and Development. Becky was a instrumental participant in the International Council on Harmonization (ICH) M4E(R2) effort, significantly contributing to the updated presentation of benefit-risk information in the clinical overview.